Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5669 - Verification of guideline conform mCRC treatment with EGFR inhibitors with real-world evidence data from EU5 countries

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Laura Hoyer

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

L. Hoyer, N. Schmidt

Author affiliations

  • Bu Oncology, Real World Insights, IQVIA Commercial GmbH & Co. OHG, 60549 - Frankfurt am Main/DE
More

Resources

Abstract 5669

Background

The EGFR inhibitors cetuximab and panitumumab are indicated for patients suffering from metastatic colorectal cancer (mCRC), which are RAS wildtype. The aim of this analysis is to verify with real-world data whether the drug usage of those EGFR inhibitors reflects clinical guidelines with regards to their genomic profile.

Methods

Anonymized patients-level data collected through a large web-based survey between April 2017 and March 2018 was used. The study reported patient case history information across all cancer types in 5EU (France, Germany, Italy, Spain & UK). Treatment information and biomarker testing information on 5248 mCRC drug treated patients were analyzed.

Results

Evaluating KRAS and NRAS biomarkers status, real-world data analysis showed that 18,9% of mCRC patients were not tested for N-RAS mutation and 11,4% were not tested for K-RAS mutation. 16% of the mCRC population were RAS mutant. However, 3,2% of these patients received cetuximab and panitumumab even though they did not qualify for this treatment, due to their RAS mutation. Among all mCRC patients who were RAS wildtype, 49,4% of them received cetuximab or panitumumab.

Conclusions

This analysis of real-word data showed that biomarkers testing is not carried out in all mCRC patients. Secondly, the use of EGFR inhibitors in the RAS mutant mCRC patient population demonstrates a misalignment with clinical guidelines. Howver, most of patients receiving EGFR inhibitors are RAS wildtype, which implies that the majority of mCRC patients receiving EGFR inhibitors is treated according to medical guidelines regarding their genomic profile.

Clinical trial identification

Legal entity responsible for the study

IQVIA Commercial GmbH & Co. OHG.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

L. Hoyer, N. Schmidt: Employee of IQVIA Commercial GmbH & Co. OHG.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings